Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). (Q47873914)

http://europepmc.org/abstract/MED/28574618

6 February 2018

title

Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). (English)

1 reference

http://europepmc.org/abstract/MED/28574618

6 February 2018

main subject

enzyme replacement therapy

0 references

author

Stefania Mondello

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Marina Mora

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Michela Ripolone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Simona Saredi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Massimiliano Filosto

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Stefano C. Previtali

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Monica Sciacco

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

R Violano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

D Ronchi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

A Nascimbeni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

I Colombo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

G Fagiolari

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

A Bordoni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

F Fortunato

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

V Lucchini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

O Musumeci

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

P Tonin

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

T Mongini

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

L Morandi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

C Angelini

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

M Sandri

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

A Toscano

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

G P Comi

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

M Moggio

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

2 June 2017

1 reference

http://europepmc.org/abstract/MED/28574618

6 February 2018

published in

Neuropathology and Applied Neurobiology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

449-462

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

12 June 2020

cites work

1 reference

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients

21 January 2018

1 reference

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

21 January 2018

1 reference

Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD).

21 January 2018

1 reference

Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail

21 January 2018

1 reference

Enzyme replacement therapy in the mouse model of Pompe disease

21 January 2018

1 reference

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

21 January 2018

1 reference

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

21 January 2018

1 reference

Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.

21 January 2018

1 reference

Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review

21 January 2018

1 reference

Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.

21 January 2018

1 reference

The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients

21 January 2018

1 reference

Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study

21 January 2018

1 reference

Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients

21 January 2018

1 reference

Quantification of muscle pathology in infantile Pompe disease.

21 January 2018

1 reference

When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease

21 January 2018

1 reference

Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies

21 January 2018

1 reference

The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII).

21 January 2018

1 reference

New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy

21 January 2018

1 reference

36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy

21 January 2018

1 reference

Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy.

21 January 2018

1 reference

Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy

21 January 2018

1 reference

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

21 January 2018

1 reference

Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.

21 January 2018

1 reference

Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy

21 January 2018

1 reference

Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype

21 January 2018

1 reference

A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations

21 January 2018

1 reference

21 January 2018

1 reference

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

21 January 2018

1 reference

Therapeutic approaches in glycogen storage disease type II/Pompe Disease.

21 January 2018

1 reference

2007 Universal Myocardial Infarction Definition Change Criteria for Risk Stratification by Use of a High-Sensitivity Cardiac Troponin I Assay

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/NAN.12414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28574618%20AND%20SRC:MED&resulttype=core&format=json

release_34v2uszszzbmxcddla7s6dfkwi

12 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/34v2uszszzbmxcddla7s6dfkwi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference